ImmunoForge Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Series C

  • Investors
  • 12

ImmunoForge General Information

Description

Operator of a drug development and pharmaceutical company intended to develop drugs for treating sarcopenia and cancer. The company's drugs specialize in targeting Duchenne muscular dystrophy, ALS, senile sarcopenia, polymyositis, cancer cachexia, and genomically defined rare cancers such as chronic myelogenous leukemia, enabling pharmaceutical companies to develop biologics with reduced dosing frequency and improved patient adherence.

Contact Information

Website
www.immunoforge.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rooms 1701-1707, Ace Hansol Tower, 58
  • Gasandigital 1-ro, Geumcheon-gu
  • Seoul, 08591
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Rooms 1701-1707, Ace Hansol Tower, 58
  • Gasandigital 1-ro, Geumcheon-gu
  • Seoul, 08591
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunoForge Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series C) 30-Sep-2025 Completed Clinical Trials - Phase 1
9. Secondary Transaction - Private Completed Clinical Trials - Phase 1
8. Early Stage VC (Series B) 01-Aug-2021 Completed Clinical Trials - Phase 1
7. Early Stage VC 01-Oct-2020 Completed Clinical Trials - Phase 1
6. Early Stage VC 01-Jul-2020 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A) 01-Mar-2019 Completed Clinical Trials - Phase 1
4. Grant 01-Jan-2018 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 28-Dec-2017 Completed Clinical Trials - Phase 1
2. Corporate 01-Dec-2017 Completed Clinical Trials - Phase 1
1. University Spin-Out 29-May-2017 Completed Startup
To view ImmunoForge’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

ImmunoForge Patents

  • 93

    Total Documents Applications and Grants

  • Total Patents Families

  • 62

    Granted

  • 19

    Pending

  • Expiring in next 12 mo

ImmunoForge Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4520350-A1 Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof Pending 04-May-2022
EP-4520350-A4 Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof Pending 04-May-2022
US-20250289861-A1 Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof Pending 04-May-2022
WO-2023214833-A1 Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof Inactive 04-May-2022
EP-4257598-A1 Fusion protein including glp-1 receptor agonist and anti-oscar antibody, and use thereof Pending 03-Dec-2020 C07K14/605
To view ImmunoForge’s complete patent history, request access »

ImmunoForge Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunoForge Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
AJU IB Investment Venture Capital Minority
IMM Investment Asset Manager Minority
Kiwoom Investment Venture Capital Minority
We Ventures (Korea) Venture Capital Minority
Korea Omega Investment Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

ImmunoForge Investments (1)

ImmunoForge’s most recent deal was a Corporate Asset Purchase with PhaseBio Pharmaceuticals (ELP Platform). The deal was made on 01-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PhaseBio Pharmaceuticals (ELP Platform) 01-Feb-2023 Corporate Asset Purchase Buildings and Property
To view ImmunoForge’s complete investments history, request access »

Ready to get started?

Request a free trial

ImmunoForge FAQs

  • When was ImmunoForge founded?

    ImmunoForge was founded in 2017.

  • Where is ImmunoForge headquartered?

    ImmunoForge is headquartered in Seoul, South Korea.

  • What is the size of ImmunoForge?

    ImmunoForge has 19 total employees.

  • What industry is ImmunoForge in?

    ImmunoForge’s primary industry is Drug Discovery.

  • Is ImmunoForge a private or public company?

    ImmunoForge is a Private company.

  • What is ImmunoForge’s current revenue?

    The current revenue for ImmunoForge is .

  • How much funding has ImmunoForge raised over time?

    ImmunoForge has raised $27.8M.

  • Who are ImmunoForge’s investors?

    AJU IB Investment, IMM Investment, Kiwoom Investment, We Ventures (Korea), and Korea Omega Investment are 5 of 12 investors who have invested in ImmunoForge.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process